SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-220072
Filing Date
2022-08-12
Accepted
2022-08-12 17:03:57
Documents
18
Period of Report
2022-08-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d390163d8k.htm   iXBRL 8-K 31076
2 EX-1.1 d390163dex11.htm EX-1.1 177271
3 EX-5.1 d390163dex51.htm EX-5.1 5612
4 EX-99.1 d390163dex991.htm EX-99.1 13093
5 EX-99.2 d390163dex992.htm EX-99.2 14967
6 EX-99.3 d390163dex993.htm EX-99.3 12985
7 EX-99.4 d390163dex994.htm EX-99.4 13678
  Complete submission text file 0001193125-22-220072.txt   465316

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA cere-20220810.xsd EX-101.SCH 2857
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE cere-20220810_lab.xml EX-101.LAB 17995
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cere-20220810_pre.xml EX-101.PRE 11262
12 EXTRACTED XBRL INSTANCE DOCUMENT d390163d8k_htm.xml XML 3364
Mailing Address 222 JACOBS STREET SUITE 200 CAMBRIDGE MA 02141
Business Address 222 JACOBS STREET SUITE 200 CAMBRIDGE MA 02141 844-304-2048
Cerevel Therapeutics Holdings, Inc. (Filer) CIK: 0001805387 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39311 | Film No.: 221161100
SIC: 2834 Pharmaceutical Preparations